No Cover Image

Journal article 33 views 3 downloads

Studying the Long-term Impact of COVID-19 in Kids (SLICK). Healthcare use and costs in children and young people following community-acquired SARS-CoV-2 infection: protocol for an observational study using linked primary and secon...

Olivia V Swann Orcid Logo, Nazir I Lone, Ewen M Harrison Orcid Logo, Laurie A Tomlinson Orcid Logo, Alex J Walker Orcid Logo, Mike Seaborne Orcid Logo, Louisa Pollock, James Farrell, Peter S Hall, Sohan Seth, Thomas C Williams, Jennifer Preston, J. Samantha Ainsworth, Freya F Semple, J Kenneth Baillie, Srinivasa V Katikireddi Orcid Logo, Ashley Akbari Orcid Logo, Ronan Lyons Orcid Logo, Colin R Simpson Orcid Logo, Malcolm G Semple, Ben Goldacre Orcid Logo, Sinead Brophy Orcid Logo, Aziz Sheikh, Annemarie B Docherty

BMJ Open, Volume: 12, Issue: 11, Start page: e063271

Swansea University Authors: Mike Seaborne Orcid Logo, Ashley Akbari Orcid Logo, Ronan Lyons Orcid Logo, Sinead Brophy Orcid Logo

  • 61931.pdf

    PDF | Version of Record

    © Author(s) (or their employer(s)) 2022. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license

    Download (965.74KB)

Abstract

Introduction SARS-CoV-2 infection rarely causes hospitalisation in children and young people (CYP), but mild or asymptomatic infections are common. Persistent symptoms following infection have been reported in CYP but subsequent healthcare use is unclear. We aim to describe healthcare use in CYP fol...

Full description

Published in: BMJ Open
ISSN: 2044-6055 2044-6055
Published: BMJ 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa61931
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: Introduction SARS-CoV-2 infection rarely causes hospitalisation in children and young people (CYP), but mild or asymptomatic infections are common. Persistent symptoms following infection have been reported in CYP but subsequent healthcare use is unclear. We aim to describe healthcare use in CYP following community-acquired SARS-CoV-2 infection and identify those at risk of ongoing healthcare needs.Methods and analysis We will use anonymised individual-level, population-scale national data linking demographics, comorbidities, primary and secondary care use and mortality between 1 January 2019 and 1 May 2022. SARS-CoV-2 test data will be linked from 1 January 2020 to 1 May 2022. Analyses will use Trusted Research Environments: OpenSAFELY in England, Secure Anonymised Information Linkage (SAIL) Databank in Wales and Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 in Scotland (EAVE-II). CYP aged ≥4 and <18 years who underwent SARS-CoV-2 reverse transcription PCR (RT-PCR) testing between 1 January 2020 and 1 May 2021 and those untested CYP will be examined.The primary outcome measure is cumulative healthcare cost over 12 months following SARS-CoV-2 testing, stratified into primary or secondary care, and physical or mental healthcare. We will estimate the burden of healthcare use attributable to SARS-CoV-2 infections in the 12 months after testing using a matched cohort study of RT-PCR positive, negative or untested CYP matched on testing date, with adjustment for confounders. We will identify factors associated with higher healthcare needs in the 12 months following SARS-CoV-2 infection using an unmatched cohort of RT-PCR positive CYP. Multivariable logistic regression and machine learning approaches will identify risk factors for high healthcare use and characterise patterns of healthcare use post infection.Ethics and dissemination This study was approved by the South-Central Oxford C Health Research Authority Ethics Committee (13/SC/0149). Findings will be preprinted and published in peer-reviewed journals. Analysis code and code lists will be available through public GitHub repositories and OpenCodelists with meta-data via HDR-UK Innovation Gateway.
College: Faculty of Medicine, Health and Life Sciences
Funders: This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). This work was also supported by The Alan Turing Institute via ‘Towards Turing 2.0’ EPSRC Grant Funding. The grant period spans 1 November 2021 to 30 September 2022.
Issue: 11
Start Page: e063271